Extracellular vesicle biomarkers of Alzheimer's disease associated with sub-clinical cognitive decline in late middle age
JournalAlzheimer's and Dementia
PublisherJohn Wiley and Sons Inc.
MetadataShow full item record
AbstractIntroduction: Neuronal extracellular vesicle (nEV) tau and insulin signaling biomarkers may detect preclinical Alzheimer's disease and age-associated cognitive decline. Methods: This case-control study used repeated serum samples from 73 cognitively declining and 73 stable Wisconsin Registry for Alzheimer's Prevention participants (62.4 ± 6.3 years old). We immunocaptured nEVs; measured tau and insulin signaling biomarkers; and examined biomarker differences by group, their performance in group classification in training and test datasets (97, 49 individuals, respectively), and whether they predict cognitive performance change. Results: Declining compared to stable individuals showed higher baseline total, p231-, and p181-tau with older age and higher annualized change for p-IR and p-IGF-1R. Combining biomarkers classified decliners with 94% area under the curve (AUC), 86.0% sensitivity and 86.7% specificity, in training data, and 75% AUC, 71.4% sensitivity, and 77.3% specificity, in test data. Insulin biomarkers predicted cognitive performance change prospectively. Discussion: Combining nEV biomarkers can identify individuals with age-associated cognitive decline.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85087174414&doi=10.1002%2falz.12130&partnerID=40&md5=9a9a6cd9c09f4630ed1b75f7c59e3b6b; http://hdl.handle.net/10713/13315